Journal of Thrombosis and Thrombolysis

, Volume 25, Issue 1, pp 37–44

Treatment of DVT: how long is enough and how do you predict recurrence

Article

Abstract

Currently available anticoagulants are effective in reducing the recurrence rate of venous thromboembolism (VTE). However, anticoagulant treatment is associated with an increased risk for bleeding complications. Thus, anticoagulation has to be discontinued when benefit of treatment no longer clearly outweigh its risks. The duration of anticoagulant treatment is currently framed based on the estimated individual risk for recurrent VTE. The incidence of recurrent VTE can be estimated through a two-step decision algorithm. Firstly, the features of the patient (gender), of the initial event (proximal or distal deep vein thrombosis or pulmonary embolism), and the associated conditions (cancer, surgery, etc) provide essential information on the risk for recurrence after anticoagulant treatment discontinuation. Secondly, at time of anticoagulant treatment discontinuation, d-dimer levels and residual thrombosis have been indicated as predictors of recurrent VTE. Current evidence suggests that the risk of recurrence after stopping therapy is largely determined by whether the acute episode of VTE has been effectively treated and by the patient’s intrinsic risk of having a new episode of VTE. All patients with acute VTE should receive oral anticoagulant treatment for three months. At the end of this treatment period, physicians should decide for withdrawal or indefinite anticoagulation. Based on intrinsic patient’s risk for recurrent VTE and for bleeding complications and on patient preference, selected patients could be allocated to indefinite treatment with VKA with scheduled periodic re-assessment of the benefit from extending anticoagulation. Alternative strategies for secondary prevention of VTE to be used after conventional anticoagulation are currently under evaluation. Cancer patients should receive low molecular-weight heparin over warfarin in the long-term treatment of VTE. These patients should be considered for extended anticoagulation at least until resolution of underlying disease.

Abbreviated abstract

The risk for recurrent venous thromboembolism can be estimated through a two-step algorithm. Firstly, the features of the patient (gender), of the initial event (proximal or distal deep vein thrombosis or pulmonary embolism), and the associated conditions (cancer, surgery, etc) are essential to estimate the risk for recurrence after anticoagulant treatment discontinuation. Secondly, a correlation has been shown between d-dimer levels and residual thrombosis at time of anticoagulant treatment discontinuation and the risk of recurrence. Currently available anticoagulants are effective in reducing the incidence of recurrent venous thromboembolism, but they are associated with an increased risk for bleeding complications. All patients with acute venous thromboembolism should receive oral anticoagulant treatment for three months. At the end of this treatment period physicians should decide for definitive withdrawal or indefinite anticoagulation with scheduled periodic re-assessment of the benefit from extending anticoagulation.

Keywords

Venous thromboembolism Warfarin Deep vein thrombosis Pulmonary embolism 

References

  1. 1.
    Lagerstedt CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U (1985) Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 2:515–518PubMedCrossRefGoogle Scholar
  2. 2.
    Hull R, Delmore T, Genton E et al (1979) Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 301:855–858PubMedCrossRefGoogle Scholar
  3. 3.
    Silverstein MD, Heit JA, Mohr DN et al (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158:585–593PubMedCrossRefGoogle Scholar
  4. 4.
    Anderson FA Jr., Wheeler HB, Goldberg RJ et al (1991) A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 151:933–938PubMedCrossRefGoogle Scholar
  5. 5.
    Kniffin WD Jr., Baron JA, Barrett J et al (1994) The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 154:861–866PubMedCrossRefGoogle Scholar
  6. 6.
    Hansson PO, Welin L, Tibblin G et al (1997) Deep vein thrombosis and pulmonary embolism in the general population. “The Study of Men Born in 1913.” Arch Intern Med 157:1665–1670PubMedCrossRefGoogle Scholar
  7. 7.
    White RH, Zhou H, Romano PS (1998) Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med 128:737–740PubMedGoogle Scholar
  8. 8.
    Cushman M, Tsai A, White R et al (2004) Deep vein thrombosis and pulmonary embolism in two cohorts: the Longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Med 117:19–25PubMedCrossRefGoogle Scholar
  9. 9.
    Heit J, Silverstein M, Mohr D, Petterson T, O’Fallon W, Melton L III (2000) Risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med 160:80915Google Scholar
  10. 10.
    Prandoni P, Lensing AWA, Cogo A et al (1996) The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125:1–7PubMedGoogle Scholar
  11. 11.
    Schulman S, Rhedin A-S, Lindmarker P et al (1995) A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 332:1661–1665PubMedCrossRefGoogle Scholar
  12. 12.
    Pinede L, Ninet J, Duhaut P et al (2001) Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 103:2453–2460PubMedGoogle Scholar
  13. 13.
    Agnelli G, Prandoni P, Becattini C et al (2003) Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 139:19–25PubMedGoogle Scholar
  14. 14.
    Christiansen S, Cannegieter S, Koster T, Vanderbroucke J, Rosendaal F (2005) Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 293: 2352–2361PubMedCrossRefGoogle Scholar
  15. 15.
    Kearon C, Gent M, Hirsh J et al (1999) A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340:901–907PubMedCrossRefGoogle Scholar
  16. 16.
    Agnelli G, Prandoni P, Santamaria MG et al (2001) Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 345:165–169PubMedCrossRefGoogle Scholar
  17. 17.
    Lee AYY, Levine MN, Baker RI et al (2003) Low-molecular weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146–153PubMedCrossRefGoogle Scholar
  18. 18.
    Simioni P, Prandoni P, Lensing AW et al (1997) The risk of recurrent venous thromboembolism in patients with an Arg506–>Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 336:399–403PubMedCrossRefGoogle Scholar
  19. 19.
    De Stefano V, Martinelli I, Mannucci PM et al (1999) The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 341:801–806PubMedCrossRefGoogle Scholar
  20. 20.
    Crowther MA, Kelton JG (2003) Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. Ann Intern Med 138:128–134PubMedGoogle Scholar
  21. 21.
    Baglin T, Luddington R, Brown K, Baglin C (2003) Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 362:523–526PubMedCrossRefGoogle Scholar
  22. 22.
    Kearon C, Ginsberg JS, Kovacs MJ et al (2003) Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349:631–639PubMedCrossRefGoogle Scholar
  23. 23.
    Ridker PM, Goldhaber SZ, Danielson E et al (2003) Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 348:1425–1434PubMedCrossRefGoogle Scholar
  24. 24.
    Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW (2006) Risk of recurrent venous thromboembolism in patients with common thrombophilia. A systematic review. Arch Intern Med 166:729–736PubMedCrossRefGoogle Scholar
  25. 25.
    Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S (2004) The risk of recurrent venous thromboembolism in men and women. N Engl J Med 350:2558–2563PubMedCrossRefGoogle Scholar
  26. 26.
    Baglin T, Luddington R, Brown K, Baglin C (2004) High risk of recurrent venous thromboembolism in men. J Thromb Haemost 2:2152–2155PubMedCrossRefGoogle Scholar
  27. 27.
    McRae S, Tran H, Schulman S, Ginsberg J, Kearon K (2006) Effect of patient’s sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet 368:371–378PubMedCrossRefGoogle Scholar
  28. 28.
    Murin S, Romano PS, White RH (2002) Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. Thromb Haemost 88:407–414PubMedGoogle Scholar
  29. 29.
    Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS (1998) Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 279:458–462PubMedCrossRefGoogle Scholar
  30. 30.
    Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ III (1999) Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 159:445–453PubMedCrossRefGoogle Scholar
  31. 31.
    Research Committee of the British Thoracic Society (1992) Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 340:873–876Google Scholar
  32. 32.
    Levine MN, Hirsh J, Gent M et al (1995) Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 74:606–611PubMedGoogle Scholar
  33. 33.
    Ost G, Tepper J, Mihara H, Lander O, Heinzer R, Fein A (2005) Duration of anticoagulation after venous thromboembolism. A meta-analysis. JAMA 294:706–715PubMedCrossRefGoogle Scholar
  34. 34.
    Van Dongen C, Vink R, Hutten B, Buller H, Prins M (2003) The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event. Arch Intern Med 163:1285–1293PubMedCrossRefGoogle Scholar
  35. 35.
    Campbell IA, Bentley DP, Prescott RJ, Routledge PA, Shetty HGM, Williamson IJ (2007) Anticoagulation for three versus six months in patients with deep-vein thrombosis or pulmonary embolism, or both, randomized trial. BMJ 334:674PubMedCrossRefGoogle Scholar
  36. 36.
    Linkins L, Choi PT, Douketis JD (2003) Clinical impact of bleeding in patients taking oral anticoagulant therapy for with venous thromboembolism: a meta-analysis. Ann Intern Med 139:893–900PubMedGoogle Scholar
  37. 37.
    Palareti G, Legnani C, Cosmi B et al (2002) Risk of venous thromboembolism recurrence: high negative predictive value of d-dimer performed after oral anticoagulation is stopped. Thromb Haemost 87:7–12PubMedGoogle Scholar
  38. 38.
    Palareti G, Cosmi C, Legnani et al, For the PROLONG investigators (2006) d-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 355:1780–1789PubMedCrossRefGoogle Scholar
  39. 39.
    Prandoni P, Lensing AW, Prins MH et al (2002) Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 137:955–960PubMedGoogle Scholar
  40. 40.
    Schulman S, Svenungsson E, Granqvist S (1998) Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of anticoagulation study group. Am J Med 104:332–338PubMedCrossRefGoogle Scholar
  41. 41.
    Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR (1995) The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332:993–997PubMedCrossRefGoogle Scholar
  42. 42.
    Becattini C, Agnelli G, Prandoni P et al (2005) A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J 26:77–83PubMedCrossRefGoogle Scholar
  43. 43.
    Prandoni P, Ghirarduzzi A, Prins MH et al (2006) Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J Thromb Haemost 4:1891–1896PubMedCrossRefGoogle Scholar
  44. 44.
    Prandoni P, Lensing AWA, Piccioli A et al (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484–3488PubMedCrossRefGoogle Scholar
  45. 45.
    Lee AYY, Levine MN, Baker RI et al (2003) Low-molecular weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146–153PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Division of Internal and Cardiovascular MedicineUniversity of PerugiaPerugiaItaly

Personalised recommendations